MedPath

ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD.

🇨🇳China
Ownership
-
Established
1993-01-09
Employees
831
Market Cap
-
Website
www.conbapharm.com
Introduction

The company was formerly known as Lanxi Yunshan Pharmaceutical Factory. After more than 50 years of development, it has now grown into the largest traditional Chinese medicine enterprise in the province integrating drug research and development, production and sales. It ranks among the top 10 Chinese medicine enterprises in China, and has been selected as a “model enterprise for scientific reform” of state-owned enterprises under the State Council. The company is mainly engaged in R&D, manufacturing and sales of pharmaceuticals, Chinese medicine tablets and health products. The company's main products are “Qianlekang” brand Puleam tablets and capsules, “Tianbaoning” brand ginkgo biloba preparations, “Kangenbei” brand enteritis, “Jinaokang” brand omeprazole products, “Golden Dipper” brand compound houttuynia cordata, “Jinkang Speed” brand acetylcysteine effervescent tablets, “Zhixincang” brand musk cysteine effervescent tablets, “Kangenbei”, “Baozhilin”, “Yangtang” brand health camp series Food and functional foods. Corporate honors: Hu Jiqiang won the “Global Zhejiang Merchants Gold Award”, the 11th China Main Board Listed Company Top 100 Value Gold Award, the Zhejiang Red Cross Fraternity Merit Gold Award, 2016 Advanced Unit for the Integration of “Two Modernizations”, and the 2017 China Top 500 Brands Ranking, Conn Bell ranked 312th.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

103

NMPA:103

Drug Approvals

清喉咽含片

Approval Number
国药准字Z20250005
Approval Date
May 20, 2025
NMPA

Vonoprazan Fumarate Tablets

Product Name
富马酸伏诺拉生片
Approval Number
国药准字H20253897
Approval Date
Apr 15, 2025
NMPA

Vonoprazan Fumarate Tablets

Product Name
富马酸伏诺拉生片
Approval Number
国药准字H20253896
Approval Date
Apr 15, 2025
NMPA

野马追颗粒

Approval Number
国药准字Z20050420
Approval Date
Sep 3, 2024
NMPA

Compound Dyclonine Hydrochloride and Monthal Solution

Product Name
复方达克罗宁薄荷溶液
Approval Number
国药准字H33022133
Approval Date
Sep 3, 2024
NMPA

积雪苷霜软膏

Approval Number
国药准字Z20053708
Approval Date
Sep 3, 2024
NMPA

Atomoxetine Hydrochloride Oral Solution

Product Name
盐酸托莫西汀口服溶液
Approval Number
国药准字H20244163
Approval Date
Jun 28, 2024
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20243763
Approval Date
Jun 19, 2024
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20243648
Approval Date
Apr 30, 2024
NMPA

Risperidone Oral Solution

Product Name
利培酮口服液
Approval Number
国药准字H20233562
Approval Date
May 19, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 11
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.